ARS Pharmaceuticals (SPRY) News Today

ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) shares moved lower as investors weighed a wider-than-expected quarterly loss and a wave of securities-class-action notices, despite continued growth for its needle-free epinephrine product, neffy.

• Positive Sentiment: neffy revenue exceeded expectations. ARS reported $26.2 million in U.S. neffy net product revenue for the second quarter, while total U.S. epinephrine market share for Type 1 allergies reached 5%, including 8% in field-targeted accounts. The company also outlined a more focused commercial strategy. ARS Pharmaceuticals Q2 results and strategic priorities
• Neutral Sentiment: Revenue beat analyst expectations. Second-quarter revenue was $33.66 million, above the $31.32 million consensus estimate, indicating solid commercial momentum for neffy. However, revenue growth did not offset the company’s substantially higher expenses. ARS Pharmaceuticals Q2 earnings report
• Negative Sentiment: The quarterly loss was worse than expected and widened year over year. ARS reported a loss of $0.63 per share, compared with an expected loss of approximately $0.48-$0.55 per share and a $0.46 loss in the prior-year quarter. The company posted a negative net margin and return on equity, reinforcing concerns about ongoing profitability and cash-burn risk. ARS Pharmaceuticals Q2 net loss and revenue
• Negative Sentiment: Multiple law firms publicized a securities class action against ARS. The lawsuit covers investors who purchased shares between March 9 and June 24, 2026, and alleges that the company’s statements about a July 1 CVS Caremark formulary date were misleading or inadequately qualified. The lead-plaintiff deadline is October 5, 2026. The litigation adds legal, financial, and reputational uncertainty and appears to be the most immediate source of investor pressure. Kaplan Fox class action notice